Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment
Background/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Multidisciplinary Digital Publishing Institute
2025
|
| Online Access: | https://hdl.handle.net/1721.1/158152 |
| _version_ | 1824457929949970432 |
|---|---|
| author | Wen, Qing Karcher, Helene Wright, David M. Sinha, Samriddhi Buxy Chakravarthy, Usha Santos, Catarina Igwe, Franklin Salongcay, Recivall Curran, Katie Peto, Tunde |
| author_facet | Wen, Qing Karcher, Helene Wright, David M. Sinha, Samriddhi Buxy Chakravarthy, Usha Santos, Catarina Igwe, Franklin Salongcay, Recivall Curran, Katie Peto, Tunde |
| author_sort | Wen, Qing |
| collection | MIT |
| description | Background/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using Medisoft electronic medical records (UK), this retrospective cohort study analysed VA outcomes, changes, and determinants in DMO patients at year 1 and year 2 after initial anti-VEGF injection. Descriptive analysis examined baseline demographics and clinical characteristics, while regression models were used to assess associations between these factors and changes in VA. Results: 728 DMO patients (1035 eyes) treated with anti-VEGFs (ranibizumab, aflibercept, or bevacizumab) at the Northern Ireland Mater Macular Clinic from 2008 to 2021 were evaluated. The mean age was 64.5 (SD 12.8) years, and 59.6% were male. In the first year, the median annual injection number and interval were 6.0 (IQR 5.0–8.0) and 6.1 weeks (IQR 5.4–7.8), respectively, and in the second year, they were 3.0 (IQR 2.0–5.0) and 10.0 weeks (IQR 6.5–20.1). In the first two treatment years, 83.4% and 79.8% of eyes had improved/stable VA (ISVA) respectively. The injection number, interval, baseline VA, age, and proliferative diabetic retinopathy (PDR) significantly impacted VA outcomes. Conclusions: Our study confirms the effectiveness of anti-VEGF treatments in improving or maintaining vision for DMO patients, consistent with previous real-world clinical data. An elder age, a better baseline VA, low annual injection numbers (<5), and less frequent injection intervals (≥12 weeks) were negatively associated with ISVA success in the first two years. These findings have implications for managing patient expectations, allocating resources, and understanding DMO clinical management. |
| first_indexed | 2025-02-19T04:17:49Z |
| format | Article |
| id | mit-1721.1/158152 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2025-02-19T04:17:49Z |
| publishDate | 2025 |
| publisher | Multidisciplinary Digital Publishing Institute |
| record_format | dspace |
| spelling | mit-1721.1/1581522025-02-03T16:03:49Z Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment Wen, Qing Karcher, Helene Wright, David M. Sinha, Samriddhi Buxy Chakravarthy, Usha Santos, Catarina Igwe, Franklin Salongcay, Recivall Curran, Katie Peto, Tunde Background/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using Medisoft electronic medical records (UK), this retrospective cohort study analysed VA outcomes, changes, and determinants in DMO patients at year 1 and year 2 after initial anti-VEGF injection. Descriptive analysis examined baseline demographics and clinical characteristics, while regression models were used to assess associations between these factors and changes in VA. Results: 728 DMO patients (1035 eyes) treated with anti-VEGFs (ranibizumab, aflibercept, or bevacizumab) at the Northern Ireland Mater Macular Clinic from 2008 to 2021 were evaluated. The mean age was 64.5 (SD 12.8) years, and 59.6% were male. In the first year, the median annual injection number and interval were 6.0 (IQR 5.0–8.0) and 6.1 weeks (IQR 5.4–7.8), respectively, and in the second year, they were 3.0 (IQR 2.0–5.0) and 10.0 weeks (IQR 6.5–20.1). In the first two treatment years, 83.4% and 79.8% of eyes had improved/stable VA (ISVA) respectively. The injection number, interval, baseline VA, age, and proliferative diabetic retinopathy (PDR) significantly impacted VA outcomes. Conclusions: Our study confirms the effectiveness of anti-VEGF treatments in improving or maintaining vision for DMO patients, consistent with previous real-world clinical data. An elder age, a better baseline VA, low annual injection numbers (<5), and less frequent injection intervals (≥12 weeks) were negatively associated with ISVA success in the first two years. These findings have implications for managing patient expectations, allocating resources, and understanding DMO clinical management. 2025-02-03T16:03:47Z 2025-02-03T16:03:47Z 2025-01-13 2025-01-24T13:16:08Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/158152 Wen, Q.; Karcher, H.; Wright, D.M.; Sinha, S.B.; Chakravarthy, U.; Santos, C.; Igwe, F.; Salongcay, R.; Curran, K.; Peto, T. Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment. Pharmaceutics 2025, 17, 99. PUBLISHER_CC http://dx.doi.org/10.3390/pharmaceutics17010099 Pharmaceutics Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ application/pdf Multidisciplinary Digital Publishing Institute Multidisciplinary Digital Publishing Institute |
| spellingShingle | Wen, Qing Karcher, Helene Wright, David M. Sinha, Samriddhi Buxy Chakravarthy, Usha Santos, Catarina Igwe, Franklin Salongcay, Recivall Curran, Katie Peto, Tunde Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_full | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_fullStr | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_full_unstemmed | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_short | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_sort | visual acuity outcomes and influencing factors in a cohort of uk real world diabetic macular oedema patients during the first two years of anti vegf treatment |
| url | https://hdl.handle.net/1721.1/158152 |
| work_keys_str_mv | AT wenqing visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT karcherhelene visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT wrightdavidm visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT sinhasamriddhibuxy visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT chakravarthyusha visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT santoscatarina visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT igwefranklin visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT salongcayrecivall visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT currankatie visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT petotunde visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment |